Obesity and inflammation: A new look at an old problem

Mehta, S.; Farmer, John A.

doi:10.1007/s11883-007-0009-4

Cited by 67 publications

(56 citation statements)

References 32 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because information on residual renal function and proteinuria has not been collected, we analyzed surrogate parameters such as ultrafiltration volume, diuretic use, and time on hemodialysis. We did not detect differences of these factors across the quartiles of LDL-C and therefore consider it unlikely that residual renal function or protein loss accounted for increases in LDL-C. Alternatively, one might speculate that patients with higher LDL-C are still well nurtured (high body mass index and high phosphate) and that their adipose tissue produces proinflammatory cytokines or less adiponectin, which would in turn raise CRP and decrease albumin (34).…”

Section: Discussionmentioning

confidence: 77%

Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis

März

Genser²,

Drechsler³

et al. 2011

Clinical Journal of the American Society of Nephrology

124

View full text Add to dashboard Cite

SummaryBackground and objectives Patients undergoing maintenance hemodialysis are at high cardiovascular risk. Lowering LDL-cholesterol with statins reduces the incidence rate of cardiovascular events in patients with chronic kidney disease. In contrast, two randomized, prospective, placebo-controlled trials have been completed in hemodialysis patients that showed no significant effects of statins on cardiovascular outcomes. Design, setting, participants, & measurementsA post hoc analysis was conducted of the 4D (Die Deutsche Diabetes Dialyze) study to investigate whether LDL-cholesterol at baseline is predictive of cardiovascular events and whether the effect of atorvastatin on clinical outcomes depends on LDL-cholesterol at baseline.Results High concentrations of LDL-cholesterol by tendency increased the risks of cardiac endpoints and all-cause mortality. Concordantly, atorvastatin significantly reduced the rates of adverse outcomes in the highest quartile of LDL-cholesterol (Ն145 mg/dl, 3.76 mmol/L). The hazard ratios and 95% confidence intervals were 0.69 (0.48 to 1.00) for the composite primary endpoint, 0.58 (0.34 to 0.99) for cardiac death, 0.48 (0.25 to 0.94) for sudden cardiac death, 0.62 (0.33 to 1.17) for nonfatal myocardial infarction, 0.68 (0.47 to 0.98) for all cardiac events combined, and 0.72 (0.52 to 0.99) for death from all causes, respectively. No such decrease was seen in any of the other quartiles of LDL-cholesterol at baseline. ConclusionsIn patients with type 2 diabetes mellitus undergoing hemodialysis, atorvastatin significantly reduces the risk of fatal and nonfatal cardiac events and death from any cause if pretreatment LDL-cholesterol is Ͼ145 mg/dl (3.76 mmol/L).

show abstract

Section: Discussionmentioning

confidence: 77%

Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis

März

Genser²,

Drechsler³

et al. 2011

Clinical Journal of the American Society of Nephrology

124

View full text Add to dashboard Cite

show abstract

“…Özellikle artan yağ kitlesi ile tip II diyabet, metabolik sendrom, hipertansiyon ve astım gibi pek çok hastalığın ortaya çıkması bu durumu ispatlamaktadır 1 . Son yıllarda yapılan çalışmalarda obezitenin inflamatuvar bir durum ve yağ dokusunun immün ve endokrin bir organ olduğu öne sürülmüştür 10 . Yağ hücreleri arasında bulunan bağ dokusu hücrelerinden salgılanan ve adipokin ismi verilen proteinlerin otokrin, parakrin ve endokrin etkileri olduğu gösterilmiştir.…”

Section: Gi Riflunclassified

“…Obezitenin özellikle TNF-α, IL-6, PAI-1 ve C-reaktif-protein (CRP) değerlerini artırarak kronik orta şiddette bir inflamasyona yol açtığı gösterilmiştir. Aynı zamanda TNF-α, IL-6 ve PAI-1 düzeylerindeki yükseklik visseral yağlanmaya neden olmaktadır 10 . Psoriasis etyopatogenezinde önemli role sahip serum TNF-α yüksekliği BMI'de artışa, insülin direncine ve endotelyal hücrelerden adhezyon molekülleri salınımına neden olmaktadır 14 .…”

Section: Gi Riflunclassified

Psoriasis ve Obezite

Gürer¹,

Gökalp²

2012

Turkderm

View full text Add to dashboard Cite

ÖzetSon yıllarda metabolik sendrom ve onun komponentlerinden olan obezite ile psoriasis arasında güçlü bir ilişki olduğu düşünülmektedir. Obezite, genetik ve çevresel faktörlerin etkileşimi sonucu ortaya çıkan klinik bir bulgudur. Yağ dokusundan salgılanan adipokinlerin ve bunlar içerisinde leptinin psoriasis patogenezinde rol aldığı düşünülmektedir. Leptinin temel görevi iştahı kontrol ederek enerji dengesini sağlamaktır. Serum leptin düzeyleri yapılan çalışmalarda şiddetli psoriasisli hastalarda hafif psoriasislilere ve kontrol grubuna göre yüksek bulunmuştur. Leptin salınımının artışı sonucu ortaya çıkan biyolojik olayların psoriasis için karakteristik olan keratinosit proliferasyonunu tetiklediğine dair görüşler vardır. Psoriasis ile obezite arasındaki ilişkiyi inceleyen çok sayıda klinik çalışmada bu ilişki tespit edilmiştir. Ancak bazı çalışmalar obezlerde psoriasis görülme sıklığını yüksek bulurken, sınırlı sayıdaki diğerleri psoriasisli hastalarda obezite geliştiğini tespit etmişlerdir. Bunun yanında obez psoriasisli hastaların klasik topikal ve sistemik tedaviler yanında biyolojik tedavilere verdikleri yanıt konusunda da özellikler bulunmaktadır. Sonuç olarak psoriasis ile obezite arasındaki ilişkinin leptin düzeylerinin artışı ile ortaya çıktığına ve obez psoriasisli hastaların tedavisinde kilo kontrolünün önemine dair deliller giderek artmaktadır. (Türk derm 2012; 46: 3-6) Anah tar Ke li me ler: Psoriasis, obezite, adipositokinler, leptin Sum maryIn recent years, it has been thought that a strong association exists between metabolic syndrome, specifically obesity, and psoriasis. Obesity is a multifactorial disease affected by both genetic and environmental factors. Adipokines (e.g. leptin) secreted by the adipose tissue are believed to play a role in the pathogenesis of psoriasis. The main role of leptin is to adjust metabolism by controlling appetite. Serum leptin levels in patients with severe and moderate psoriasis were found to be higher than in normal control groups. In many similar studies, leptin secretion has been found to stimulate keratinocyte proliferation, which is one of the characteristics of psoriasis. Although many studies showed increased prevalence of obesity in psoriasis patients, few others reported development of obesity in psoriasis patients. Additionally, obesity was found to affect treatment responses not only in classical systemic/topical treatment approaches in psoriasis, but also in newer biological treatments. Overall, increasing epidemiological evidence suggests strong association between obesity and psoriasis, increase in serum leptin levels is thought to have a major role, and weight loss may have significant impact on response to treatment. (Turk derm 2012; 46: 3-6

show abstract

“…Obezite kalp ve damar hastalıkları, diyabet, hipertansiyon, bazı kanser türleri, kas iskelet sistemi hastalıkları gibi hastalıkların oluşmasına, yaşam kalitesinin azalmasına ve ölümlere yol açabilmektedir. Yapılan çalışmalarda obezitenin inflamatuvar bir durum olduğu ve yağ dokusunun immün ve endokrin bir organ olduğu öne sürülmüştür 4,5 . Yağ hücreleri arasında bulunan bağ dokusu hücrelerinden salgılanan ve adipokin ismi verilen proteinlerin otokrin, parakrin ve endokrin etkileri olduğu gösterilmiştir.…”

Section: Introductionunclassified

Body mass index and psoriasis area and severity index relation in Turkish psoriasis population

Özkaya¹,

Onsun²,

Topukcu³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

Background and Design:Psoriasis is a chronic immune-mediated inflammatory disease affecting 1-3% of the general population. Recently, it has been suggested that chronic inflammation in psoriasis may cause metabolic and vascular disorders. Most of recent studies focused on the comorbidities and the mechanisms of comorbidities associated with psoriasis. Obesity may lead to cardiovascular disorders, diyabetes mellitus, hypertension, malignancies, musculoskeleteal system diseases, impaired quality of life, and death. In this study, we aimed to investigate the prevalence of obesity in patients with psoriasis and the relationship between the disease severity and body mass index (BMI) in Turkish psoriasis population. Materials and Methods:The patients who attended the Dermatovenerology outpatient clinics at Bezmialem Vakıf University Medical Faculty between February 2007 and March 2013 were enrolled in the study. We retrospectively evaluated the medical records of the patients obtained from the PSR-TR psoriasis follow-up system. Results: Five hundred forty-five women and 474 men were included in the study. The mean age of the female and male patients was 41.3 years, 43.3 years, respectively. The mean body mass index of the patients was 27.5 (26.7 for men and 28.2 for women). 54.6% of obese patients had a psoriasis area and severity index (PASI) score of less than 5, 20.5% had PASI scores between 5-10 and 24.8% had a PASI score of more than 10. Conclusion: In our study, there was a poor relationship between obesity and severity of psoriasis. The prevalence of obesity in psoriasis patients was similar to that in the Turkish population. (Turkderm 2014; 48: 127-30)

show abstract

Obesity and inflammation: A new look at an old problem

Cited by 67 publications

References 32 publications

Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis

Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis

Psoriasis ve Obezite

Body mass index and psoriasis area and severity index relation in Turkish psoriasis population

Contact Info

Product

Resources

About